pehub.com -- 3-V Biosciences, a Palo Alto, Calif.-based pharma startup whose lead candidates focus on respiratory viral infections, has raised $30 million in Series B funding. New Enterprise Associates led the round, and was joined by return backers The Column Group and Kleiner Perkins Caufield & Byers.
